Medicine guide

Mounjaro 10 mg oplossing voor injectie in injectieflacon

As listed in the register: Mounjaro 10 mg oplossing voor injectie in injectieflacon

10 mg · oplossing voor injectie

  • Prescription only
  • Digestion, stomach, diabetes and nutrition
Active substance
Tirzepatide
Made by
Eli Lilly Nederland B.V.

Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.

What it is for

Medicine groupDigestion, stomach, diabetes and nutritionA10BX16

Mediclarum has not yet retrieved and stored the official label for this product, so none of its text is shown here. Open the official leaflet

How it works

From the US prescribing label for the same active substance (Zepbound). It describes the substance, not this exact product.

Tirzepatide is a GIP receptor and GLP-1 receptor agonist.

It contains a C20 fatty diacid that enables albumin binding and prolongs the half-life.

Peak level after24 h
Half-life5–6 days
Mostly cleared after≈ 4 weeksfive half-lives — our arithmetic
PeakHalf gone4 weeks0
The shape is a standard model drawn from the two times above, not a measurement. How fast a medicine acts and wears off also depends on the dose, the form and the person.
How the body breaks it down

Tirzepatide is metabolized by proteolytic cleavage of the peptide backbone, beta-oxidation of the C20 fatty diacid, and amide hydrolysis.

Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2026-08-28

Safety of the active substance

From the US prescribing label for the same active substance (Zepbound). It describes the substance, not this exact product.

Serious warning

WARNING: RISK OF THYROID C-CELL TUMORS In rats, tirzepatide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures.

Must not be used by
  • ZEPBOUND is contraindicated in patients with: A personal or family history of MTC or in patients with MEN 2 [see Warnings and Precautions ( 5.1 )].
  • Known serious hypersensitivity to tirzepatide or any of the excipients in ZEPBOUND.
  • Serious hypersensitivity reactions, including anaphylaxis and angioedema, have been reported with tirzepatide [see Warnings and Precautions ( 5.6 ) and Adverse Reactions ( 6.2 )].
  • Personal or family history of medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia syndrome type 2 ( 4 ) Known serious hypersensitivity to tirzepatide or any of the excipients in ZEPBOUND ( 4 )

Quoted from the US prescribing label for the same active substance. Your own pack’s leaflet is the authority for your product. DailyMed

Same active substance, strength and form in other countries

Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.

Medicine passport: one printable page to show a pharmacist abroad

United StatesNo exact match for this strength and form

European UnionNo exact match for this strength and form

CanadaNo exact match for this strength and form

SwitzerlandNo exact match for this strength and form

Details

Made byEli Lilly Nederland B.V.
Active substanceTirzepatide
Used inDigestion, stomach, diabetes and nutrition
Strength10 mg
Formoplossing voor injectie
ClassificationA10BX16 · Digestion, stomach, diabetes and nutrition
Routesubcutaan gebruik
Dispensing (as stated by the register)Uitsluitend recept
RVGEU/1/22/1685

Source: Geneesmiddeleninformatiebank · 2026-09-30 · not reviewed by a clinician

Bron: College ter Beoordeling van Geneesmiddelen (CBG). De Rijksoverheid is het niet automatisch eens met de inhoud van deze site. Reuse terms: CC0 1.0 (CBG website).

Same active substance

These contain the same substance. That does not mean one can replace another — ask a pharmacist.